↓ Skip to main content
Syam Adusumilli
Cost Drivers · LFP-09.TD1

Executive Summary: Drug Pipeline and Cost Reference: Current and Emerging Therapies Affecting Level Funded Plan Economics

By Syam Adusumilli · 2 min read
Executive Summary Read the full article.

LFP-09.TD1 — The Cost Drivers
#

This technical document provides structured reference data on drugs and therapies discussed throughout Series 09, organized by therapeutic category. It is designed for periodic update as FDA approvals and pricing change. Data reflects publicly available information as of early 2026.

The document covers six categories. GLP-1 receptor agonists includes semaglutide (Ozempic and Wegovy, Novo Nordisk) and tirzepatide (Mounjaro and Zepbound, Eli Lilly), with current list prices, approved indications, administration schedules, and the announced Novo Nordisk list price reduction to $675 per month effective January 1, 2027. PCSK9 inhibitors and cardiovascular agents covers evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio), with current pricing following the 2018 reductions and the AmgenNow self-pay channel at $239 per month for evolocumab. Anti-amyloid Alzheimer’s therapies covers lecanemab (Leqembi, $26,500 annually) and donanemab (Kisunla, approximately $32,000 annually), including diagnostic requirements, monitoring protocols, and APOE e4 risk considerations. CAR-T cell therapies and gene therapies list all six commercially available CAR-T products with current prices ranging from $373,000 to $465,000, and four approved gene therapies ranging from $2.2 million to $3.1 million per treatment. The biosimilar section covers adalimumab, infliximab, ustekinumab, and oncology reference products, including PBM private-label distribution channels and documented savings data. A pipeline monitoring section identifies emerging agents, including oral orforglipron, the triple agonist retatrutide, and late-stage gene therapies for hemophilia B and Duchenne muscular dystrophy.

Consult this document when evaluating stop loss terms for policies covering potential high-cost therapies, assessing plan design implications of newly approved indications, or updating cost projections for renewal underwriting discussions.